Senseonics Holdings Inc. (SENS)
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System
Senseonics Announces First Commercial Patients Using Eversense 365 Continuous Glucose Monitor (CGM) with twiist™ Automated Insulin Delivery (AID) System
New SEC Form for ResMed Inc.
Organon conclut un accord de commercialisation pour Nilemdo® de Daiichi Sankyo en France, au Danemark, en Islande, en Suède, en Finlande et en Norvège
Organon sluit een akkoord voor de commercialisering van Daiichi Sankyo’s Nilemdo® in Frankrijk, Denemarken, IJsland, Zweden, Finland en Noorwegen
Organon sottoscrive un accordo di commercializzazione relativo a Nilemdo® di Daiichi Sankyo in Francia, Danimarca, Islanda, Svezia, Finlandia e Norvegia
Organon schließt Vermarktungsvereinbarung für Nilemdo® von Daiichi Sankyo in Frankreich, Dänemark, Island, Schweden, Finnland und Norwegen
Organon firma un acuerdo de comercialización para Nilemdo® de Daiichi Sankyo en Francia, Dinamarca, Islandia, Suecia, Finlandia y Noruega
Reviva Announces Publication on Clinical Vocal Biomarker Data from the RECOVER Phase 3 Clinical Trial